These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20430122)

  • 1. Optimal vaccine stockpile design for an eradicated disease: application to polio.
    Tebbens RJ; Pallansch MA; Alexander JP; Thompson KM
    Vaccine; 2010 Jun; 28(26):4312-27. PubMed ID: 20430122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polio control after certification: major issues outstanding.
    Fine PE; Oblapenko G; Sutter RW
    Bull World Health Organ; 2004 Jan; 82(1):47-52. PubMed ID: 15106300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.
    Thompson KM; Duintjer Tebbens RJ
    Medscape J Med; 2008; 10(8):190. PubMed ID: 18924642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A vision of a world without polio: the OPV cessation strategy.
    Heymann DL; Sutter RW; Aylward RB
    Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poliovirus vaccination during the endgame: insights from integrated modeling.
    Duintjer Tebbens RJ; Thompson KM
    Expert Rev Vaccines; 2017 Jun; 16(6):577-586. PubMed ID: 28437234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).
    Alexander L; Birkhead G; Guerra F; Helms C; Hinman A; Katz S; LeBaron CW; Modlin J; Murphy TV; ;
    Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1106-12. PubMed ID: 15583093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs of future polio risk management policies.
    Tebbens RJ; Sangrujee N; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling.
    Thompson KM; Duintjer Tebbens RJ; Pallansch MA; Kew OM; Sutter RW; Aylward RB; Watkins M; Gary H; Alexander JP; Venczel L; Johnson D; Cáceres VM; Sangrujee N; Jafari H; Cochi SL
    Risk Anal; 2006 Dec; 26(6):1571-80. PubMed ID: 17184398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [End phase challenges of poliomyelitis eradication programme realization].
    Jarzabek Z
    Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case for developing antiviral drugs against polio.
    Collett MS; Neyts J; Modlin JF
    Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of routine polio immunization in the post-certification era.
    Sutter RW; Cáceres VM; Mas Lago P
    Bull World Health Organ; 2004 Jan; 82(1):31-9. PubMed ID: 15106298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible global strategies for stopping polio vaccination and how they could be harmonized.
    Cochi SL; Sutter RW; Aylward RB
    Dev Biol (Basel); 2001; 105():153-8; discussion 159. PubMed ID: 11763323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission.
    Aylward RB; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):40-6. PubMed ID: 15106299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of response scenarios to potential polio outbreaks using mathematical models.
    Thompson KM; Duintjer Tebbens RJ; Pallansch MA
    Risk Anal; 2006 Dec; 26(6):1541-56. PubMed ID: 17184396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.